A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis who Achieve Complete Clearance on Biologics
18 Years - 100 Years
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Aug 2017 by AstraZeneca Pharmaceuticals
No locations available
|Moderate to Severe Plaque Psoriasis|
Prospective cohort study of usual care for subjects initiating therapy for plaque psoriasis on approved biologic agents. A non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.